SYMPTOMATIC HYPOCALCAEMIA FOLLOWING INTRAVENOUS ADMINISTRATION OF ZOLEDRONIC ACID IN A FEMALE PATIENT WITH OSTEOPOROSIS

被引：0

作者：

Senates, Banu Erkalma ^{[1
]}

Dogan, Abdullah ^{[2
]}

Senates, Ebubekir ^{[3
]}

机构：

[1] Diyarbakir Educ & Res Hosp, Dept Internal Med, Diyarbakir, Turkey

[2] Dicle Univ, Fac Med, Dept Internal Med, Diyarbakir, Turkey

[3] Istanbul Medeniyet Univ, Goztepe Educ & Res Hosp, Dept Gastroenterol, Istanbul, Turkey

来源：

ACTA MEDICA MEDITERRANEA | 2015年 / 31卷 / 04期

关键词：

Zoledronic Acid; Osteoporosis; Hypocalcaemia; POSTMENOPAUSAL OSTEOPOROSIS; BISPHOSPHONATE THERAPY; FRACTURES; EPIDEMIOLOGY; ALENDRONATE; WOMEN;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bisphosphonates (BPs) are widely used in the treatment of postmenopausal osteoporosis. Zoledronic acid has the highest affinity with the bone as well as alters mineral surface properties, allowing greater adsorption. A 58-year-old woman presented with osteoporosis, was treated with a once-a-year IV of 5 mg of Zoledronic Acid. Before this once-a-year treatment, her serum calcium levels were normal although after the treatment, she was hospitalized with nausea, perioral and acral paresthesias and tingling. Biochemical analysis recorded Calcium levels as 5.94 mg/dl and low levels of vitamin D Serum. The Hypocalcaemia was initially treated with IV Calcium Gluconate solution followed by oral calcium and vitamin D supplements.

引用

页码：895 / 898

页数：4

共 22 条

[1]

[Anonymous], 2010, PACKAGE INSERT RECLA

[2]

[Anonymous], 2010, CLIN GUID PREV TREAT

[3]

[Anonymous], 1863, NYDTr

[4]

[Anonymous], ONC YEARL ZOL AC PRE

[5] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[6] Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].

Bone, HG ;

Hosking, D ;

Devogelaer, J ;

Tucci, JR ;

Emkey, RD ;

Tonino, RP ;

Rodriguez-Portales, JA ;

Downs, RW ;

Gupta, J ;

Santora, AC ;

Liberman, UA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199

[7] Gaps in treatment among users of osteoporosis medications: The dynamics of noncompliance [J].

Brookhart, M. Alan ;

Avorn, Jerry ;

Katz, Jeffrey N. ;

Finkelstein, Joel S. ;

Arnold, Marilyn ;

Polinski, Jennifer M. ;

Patrick, Amanda R. ;

Mogun, Helen ;

Solmon, Daniel H. .

AMERICAN JOURNAL OF MEDICINE, 2007, 120 (03) :251-256

[8]

Burge R, 2005, J BONE MINER RES

[9]

Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]

[10] Drug insight: bisphosphonates for postmenopausal osteoporosis [J].

Chapurlat, RD ;

Delmas, PD .

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (04) :211-219

← 1 2 3 →